CD138+ Plasma Cells: Master Cells of Antibody Production
What is CD138?
CD138, also known as Syndecan-1, is a transmembrane heparan sulfate proteoglycan and a key surface marker of plasma cells. These CD138+ plasma cells represent the final stage of B cell differentiation and are responsible for producing antibodies. They are widely studied in immunology, hematology, and oncology for their crucial role in adaptive immunity and conditions such as multiple myeloma and other plasma cell disorders.
Functions of CD138+ Plasma Cells
- Antibody Secretion: CD138+ plasma cells release immunoglobulins (IgG, IgM, IgA), key defenders in immune protection.
- Long-Term Immunity: They persist in bone marrow and lymphoid organs, ensuring lifelong immune memory after infections or vaccines.
- Immune Regulation: These cells help regulate B cell maturation and enhance memory responses by interacting with dendritic cells and T follicular helper cells.
Clinical Relevance of CD138
- Multiple Myeloma Biomarker: CD138 is highly expressed on malignant plasma cells, making it essential in diagnosis and monitoring of multiple myeloma.
- Cell Isolation: CD138+ enrichment enables precise plasma cell separation for research and therapeutic antibody development.
- Tumor Research: CD138+ cells influence cancer microenvironments and cytokine pathways in myeloma, lymphoma, and carcinoma.
Comparison Table: B Cells vs. CD138+ Plasma Cells
| B Cells | CD138+ Plasma Cells |
|---|---|
| Express CD19, CD20 | Express CD138, lose CD20 |
| Antigen presentation | Antibody production |
| Circulating immune cells | Bone marrow–resident or tissue-based |
Genestac’s CD138+ Cell Enrichment Services
At Genestac Therapeutics, we provide GMP-grade isolation and purification of CD138+ plasma cells using advanced MACS and FACS technologies. Our services support:
- Monoclonal antibody discovery and development
- Multiple myeloma and plasma cell disorder research
- Immune profiling in chronic diseases
Conclusion
CD138+ plasma cells are central players in the body’s defense system, providing antibody production and long-term immunity. Their role as a biomarker in multiple myeloma and potential in targeted therapies makes them highly valuable in medical research and treatment. At Genestac Therapeutics, we are committed to advancing precision isolation and profiling of plasma cells to help clinicians and researchers develop innovative solutions in immunotherapy, cancer diagnostics, and regenerative treatments.
Frequently Asked Questions (FAQs)
Is CD138 only found in plasma cells?
CD138 is mainly present on plasma cells but can also be expressed on some epithelial cells and tumor types, especially in carcinomas.
How is CD138 used in cancer diagnosis?
CD138 is a widely used biomarker to identify malignant plasma cells in multiple myeloma and certain lymphomas.
What role does CD138 play in multiple myeloma?
In multiple myeloma, CD138 marks malignant plasma cells, helping doctors track disease progression and evaluate therapy responses.
How does Genestac support CD138+ research?
Genestac Therapeutics offers GMP-grade isolation and enrichment of CD138+ plasma cells to accelerate antibody discovery and cancer research.